Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has demonstrated steady growth in operating performance, with a revenue increase of 25.9% year-on-year in 2024, reaching 740 million yuan, and a net profit increase of 25.4%, amounting to 140 million yuan [5] - In Q1 2025, the company achieved a revenue of 200 million yuan, reflecting a year-on-year growth of 33.2%, and a net profit of 40 million yuan, up 4.5% year-on-year [5] - The growth in performance is attributed to the rising demand in downstream sectors such as integrated circuits and casting welding, alongside breakthroughs in domestic substitution of core components like X-ray sources [5] - The company has adjusted its profit forecasts for 2025-2026 and added a forecast for 2027, expecting net profits of 182 million yuan, 238 million yuan, and 313 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.59 yuan, 2.07 yuan, and 2.73 yuan [5] Financial Performance Summary - In 2024, the company generated revenues of 739 million yuan, with a year-on-year growth of 25.9% and a net profit of 143 million yuan, reflecting a growth of 25.4% [6] - The revenue from integrated circuits and electronic manufacturing reached 332 million yuan, growing by 40.75%, while the revenue from other sectors also showed positive growth [6] - The company has achieved significant milestones in the production of X-ray sources, with the 90kV-150kV micro-focus X-ray source entering mass production and new models being industrialized [6] - The financial projections indicate a steady increase in revenue and net profit, with a projected revenue of 980 million yuan in 2025, 1.246 billion yuan in 2026, and 1.596 billion yuan in 2027 [10] Industry Outlook - The industrial X-ray industry is expected to experience structural growth opportunities due to the increasing demand for precision testing in sectors like integrated circuits and automotive components, as well as the ongoing domestic substitution [7] - The company is well-positioned to leverage its full industry chain layout and technological innovation advantages to capture more market share through capital operations and acquisitions [7]

当精准医疗行业步入技术范式转换、政策导向重构、市场竞争裂变的三重深度调整期，华大基因 （300676）在近日发布的2024年"营收承压、战略蓄势"的阶段性财报，恰恰为观察行业转型逻辑提供了 高信息密度的切片。 穿透财报可见，公司正以"技术破壁+场景破圈+数据破局"的组合拳重构增长内核，勾勒出从"生育筛查 单极驱动"向"全生命周期精准医疗服务平台"跃迁的战略轨迹。这种在行业调整期中逆势完成技术储备 与商业范式双重迭代的能力，或将成为中国基因科技企业穿越周期、争夺全球生物经济制高点的关键胜 负手。 NIPT龙头地位稳固，三级防控体系持续深化 华大基因的临床业务以生育健康、肿瘤防控、感染检测为三大支柱。作为全球无创产前基因检测 （NIPT）技术的开创者及技术引领者，华大基因无创产前基因检测灵敏度与特异度均达国际领先水 平。 2024年，公司推出染色体非整倍体、缺失检测试剂，可以一次性检测孕妇羊水样本中的5种染色体非整 倍体和5种染色体片段缺失，填补了传统染色体核型分析和染色体微阵列分析技术的不足。 从业绩表现看，尽管生育健康业务整体收入略有波动，但细分领域增长显著。其中，三级预防业务中的 新生儿遗传病基因筛查业务营 ...

证券之星消息，根据市场公开信息及4月29日披露的机构调研信息，诺安基金近期对14家上市公司进行了调研，相关名单如下： 1）华大基因 （诺安基金参与公司业绩说明会&电话交流会） 调研纪要：华大基因在基因检测行业面临需求下降、操作复杂、价格高等问题，通过推动高通量测序全流程自动化和发布GeneT大模型提高效 率。公司在生育健康、肿瘤防控、传染性疾病防控等领域加大投入，拓展业务。Genalive中标9.5亿元外送检测订单，收入确认按样本数量，海外 业务持续扩展。毛利率下降因市场竞争加剧和医保控费，未来将通过优化产品和降本增效改善毛利率。AI提高了解读效率，降低了数据库建设和 分析成本。华大基因在肠癌、肝癌、宫颈癌等早筛产品上已有布局，多个产品获得国际认证。通过线上线下融合，华大基因将实现用户沉淀和持 续健康管理服务。133111i系统已发布，提供个性化健康管理方案，覆盖多种慢性病。 2）南山智尚 （诺安基金管理有限公司参与公司业绩解读会） 调研纪要：南山智尚一季度实现营业收入3.6亿元，净利润3,730万元，同比增长12.84%。公司出口业务占比25.49%，对等关税影响较小。新材料 业务成为业绩增长核心引擎，超高 ...

Group 1: Competitive Position and Market Strategy - The company actively responds to national "dual carbon" goals and smart manufacturing strategies, enhancing its competitive edge through innovation and customer relationship management [1] - The company aims to maintain its leading position in the electrical testing field while expanding into new business areas such as renewable energy equipment lifecycle testing and energy storage system validation [2][4] Group 2: Financial Performance and Investment - In 2024, the company's R&D investment accounted for 7.46% of its revenue, focusing on key technology areas [2] - The net profit attributable to shareholders for 2024 was 21.9978 million yuan, representing a year-on-year increase of 15.17% [2] - The top five customers contributed 13.94% to the total annual sales [6] Group 3: International Expansion and New Markets - The company has made progress in international business expansion, establishing a subsidiary in Canada and forming partnerships in Southeast Asia [3] - The company is enhancing its testing services in emerging markets, particularly in wind and solar energy sectors [6][7] Group 4: Future Growth and Strategic Planning - The company plans to strengthen its research and development capabilities and establish a robust service system to adapt to both domestic and international markets [4] - Future growth will focus on high-voltage testing and expanding into renewable energy sectors, including wind and solar [4][7] Group 5: Environmental and Social Responsibility - The company emphasizes environmental protection and sustainable development, promoting low-carbon and energy-saving certification testing services [6][7]

"大模型是对算法模型开发范式进行一次全新的变革，基于大模型的算法开发流程具有更智能、更高效、更灵活的特点。"于莉莉表示，以DeepSeek、 ChatGPT产品为代表的AI大模型热潮席卷全国，标志着人工智能技术正式进入大模型时代，现阶段的AI技术将快速被大模型技术整合、取代、颠覆，其基 本划分为：通用大模型、行业大模型、垂直大模型、专属大模型。 4月28日，由广州日报和广东省人工智能协会主办的"破圈与融合"人工智能主题论坛暨优秀案例发布会在广州报业文化中心举行。当前，人工智能正以前 所未有的速度重塑全球经济格局。从智能制造到智慧医疗，从金融科技到智慧城市，AI技术已深度融入千行百业，AI"破圈"已势不可挡，正成为推动经济 增长的重要引擎。 随着人工智能从梦想照进现实，一批实践者正在努力让人工智能更好地服务社会。活动现场，广电计量检测集团股份有限公司副总经理于莉莉在题为 《AI大模型驱动的企业数据管理及应用》的主旨演讲中指出，人工智能正从"以模型为中心"加速向"以数据为中心"转变，而"数据"从本质上决定了AI大模 型的落地水平。当前，数据要素管理及应用仍面临诸多痛点。 人工智能技术正式进入大模型时代，大模型催生 ...

Group 1 - Chengdu's delegation visited South Korea and Japan from April 21 to 28 to deepen economic and trade cooperation, focusing on electronic information, automotive, and medical aesthetics industries [1][2] - A total of 12 cooperation projects were signed between Chengdu and South Korea, with a total investment amount of 3.12 billion yuan [1][2] - Four industrial projects were signed in Chengdu, including HCT's China headquarters and testing laboratory, with a total investment of 1.21 billion yuan, covering electronic information, biomedicine, and new consumption sectors [3] Group 2 - Eight outward-oriented enterprises from Chengdu signed eight business cooperation projects with South Korean companies, amounting to 1.91 billion yuan, involving electronic information, biomedicine, and health sectors [4] - The cooperation aims to promote the production and marketing of new pharmaceuticals and medical devices from South Korea in Chengdu, while accelerating the international market expansion of Chengdu's unique products [4] - The event is seen as a platform for deepening cooperation between Chinese and South Korean enterprises, enhancing their collaboration in the global market [4]

对于亏损，思科瑞解释称，主要客户为各大军工集团下属单位及相关电子厂商，受军工行业人事调整、武器装备参数及型号调整等因素影响，军工行业处于 阶段性调整，订货需求量减少，检测订单量下滑。同时，市场竞争加剧导致部分检测业务价格下降，共同致使营业收入降低。 单季度看，2024年第四季度思科瑞实现营业收入4455.58万元，同比增长2.23%，环比增长2.05%；归母净亏损为2271.83万元，同比下降742.17%，环比下降 643.00%；扣非归母净亏损为2483.47万元，同比下降452.00%，环比下降735.83%。 4月26日，成都思科瑞微电子股份有限公司（以下简称"思科瑞"）发布2024年报。数据显示，2024年思科瑞营业收入为1.44亿元，同比下降28.40%；归母净 亏损为2100.32万元，同比下降143.90%；扣非归母净亏损为2602.10万元，同比下降161.25%；基本每股收益为-0.21元/股。 财务指标方面，2024年思科瑞毛利率为36.30%，同比下降17.67个百分点；净利率为-17.25%，同比下降40.45个百分点。 公开信息显示，思科瑞成立于2014年12月19日，上市日期为2 ...

编号：2025-007 | | 特定对象调研 | ☐分析师会议 | | --- | --- | --- | | | ☐媒体采访 | ☐业绩说明会 | | 投资者关系活动类别 | ☐新闻发布会 | ☐路演活动 | | | ☐现场参观 | | | | ☐其他 | | | 参与单位名称及人员姓名 | 恒生前海基金管理有限公司 龙江伟 | 张津铭 刘雅琪 | | | 南方基金管理股份有限公司 刘祎 | 程子航 | | | 摩根士丹利基金管理(中国)有限公司 贾昌浩 | | | | 生命保险资产管理有限公司 舒强 长城基金管理有限公司 廖瀚博 | | | | 前海人寿保险股份有限公司 姜青豆 | | | | 大成基金管理有限公司 敬思源 | | | 时间 | 2025年04月29日 10:00-12:00 | | | 地点 | 电话会议 | | | 上市公司接待人员姓名 | 董事会秘书、总会计师：魏永斌 | | | | 证券事务代表：夏明珠 | | | | 主要交流内容如下： 1.公司"双碳"业务开展情况？ 公司聚焦中长期发展战略，保持在支柱领域的竞争优势，持续 | | --- | --- | | 投资者关系活动主要 ...

Company Overview - China Lihong Inspection Holdings Limited (stock code: 1586.HK) is the first international comprehensive inspection and testing institution listed in Hong Kong, established in 2016 [1] - The company provides 24/7 professional inspection, testing, and technical consulting services to global industry leaders, supporting the green and low-carbon transformation of the industry [1] - It has established a global network with 58 branches and professional laboratories covering major trade ports and hub cities in the Asia-Pacific region, becoming the first Chinese TIC listed company with overseas layout [1] Business Segments Energy and Bulk Commodities - The company offers quality testing services, weight identification services, witnessing and joint inspection services, and other technical services across various energy and bulk commodity categories, including coal, crude oil, petrochemical products, and agricultural products [1] - Services are based on international, national, and regional industry standards [1] Clean Energy - The company has expanded its services to include testing for new energy sectors such as wind and solar power, focusing on quality testing of materials and components used in wind and solar energy projects [2] - It also conducts data collection and testing during the operational phase of wind and solar projects to enhance power generation stability [2] Environmental Protection - The environmental protection segment includes consulting and testing services, such as environmental impact assessments, soil pollution investigations, and various environmental monitoring services [2] - Services cater to industrial parks, government projects, and construction projects requiring indoor air quality assessments [2] LDAR Services - LDAR (Leak Detection and Repair) services play a crucial role in carbon reduction efforts, utilizing advanced detection technologies to identify and repair leaks in production processes [3] - This service helps control material leakage, reduce environmental pollution, and prevent economic losses for industries such as petrochemicals and pharmaceuticals [3] Climate Change Solutions - The company provides comprehensive solutions for carbon peak and carbon neutrality consulting, carbon asset development, and ESG consulting services [3] - Its services cover various industries, including power generation, petrochemicals, and construction, addressing climate change and sustainable development projects [3]

4月29日，贝瑞基因今日收盘11.93元，上涨1.19%，最新市净率2.53，总市值42.18亿元。 股东方面，截至2025年3月31日，贝瑞基因股东户数63808户，较上次增加19482户，户均持股市值35.28 万元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)21贝瑞基因-20.36-21.922.5342.18亿行业平均 47.7444.884.40101.07亿行业中值36.1535.662.2846.25亿1硕世生物-1832.01-1832.011.1336.67亿2天益医 疗-1617.63-2770.811.7320.61亿3澳华内镜-556.10278.924.4658.61亿4诺唯赞-416.32-492.392.2889.09亿5博 晖创新-319.59507.143.4146.89亿6爱朋医疗-296.17225.003.5724.30亿7奥精医疗-114.89-168.391.5221.32亿 8睿昂基因-90.84-74.581.2911.76亿9康泰医学-80.95-68.392.8953.28亿10中红医疗-66.61-53.130.84 ...